25
An introduction to PGDs and Varenicline Sarah Hudson, Acting Chief Pharmacist

An introduction to PGDs and Varenicline

  • Upload
    duante

  • View
    51

  • Download
    3

Embed Size (px)

DESCRIPTION

An introduction to PGDs and Varenicline. Sarah Hudson, Acting Chief Pharmacist. Objectives for this afternoon. PGDs in practice Varenicline. What is a PGD?. - PowerPoint PPT Presentation

Citation preview

Page 1: An introduction to PGDs and Varenicline

An introduction to PGDs and Varenicline

Sarah Hudson, Acting Chief Pharmacist

Page 2: An introduction to PGDs and Varenicline

Objectives for this afternoon

• PGDs in practice• Varenicline

Page 3: An introduction to PGDs and Varenicline

What is a PGD?• A written instruction for the supply or

administration of a medicine to a group of patients who may not be individually identified before presentation for treatment.

• Replace standing orders, group protocols, unit/department procedures, etc.

• These are now unlawful.• Supply of a POM or P other than on

prescription or PGD is a criminal offence.

Page 4: An introduction to PGDs and Varenicline

Background

• Before PGDs, law was unclear.• Practitioners administering POMs not on

individual prescription were probably breaking the law (Medicines Act 1968).

• Crown 1 recommended clarification. • Law changes came into effect August 2000.

Page 5: An introduction to PGDs and Varenicline

What do PGDs permit?

• Authorise named professionals from specified groups to supply or administer POMs other than on individual prescription from a doctor in specific circumstances.

• Supply/administration, not prescribing.• Empowering for non-prescribers.• Opportunity to ensure best practice.

Page 6: An introduction to PGDs and Varenicline

What does this mean in practice?

PGDs specify• What registered professional group can use the

PGD e.g. Pharmacists.• In what situations.• Inclusion and exclusion criteria (how would you

check).• Product to be used.• Follow up.

Page 7: An introduction to PGDs and Varenicline

When to use a PGD

• Most patients should be treated on an individual, patient-specific basis.

• “Use PGDs in limited situations where there is an advantage for patient care”.

• Patient safety must not be compromised.• Must be consistent with appropriate professional

relationships & accountability.

Page 8: An introduction to PGDs and Varenicline

How to use a PGD

• Pharmacists must work in line with GPhc Professional Standards.

• PGD must be authorised for your organisation.• You must sign the PGD.

Page 9: An introduction to PGDs and Varenicline

How to use a PGD

• No scope for interpretation, discretion or adjustment.– This is not prescribing, it is

supply/administration.• A patient excluded from treatment under a

PGD might still be treated, but only on prescription from a doctor or non-medical prescriber if applicable.

Page 10: An introduction to PGDs and Varenicline

How are PGDs produced?

• Specific requirements in legislation.• Must be produced by a doctor, pharmacist and

member of profession to which applies.• Must be authorised for use by specified senior

staff.

Page 11: An introduction to PGDs and Varenicline

Labelling of medicines

• Must use original packs (eg Levonelle) or use pre-packs from a pharmacist unless giving for immediate administration or be labelled as per labelling legislation.

• All patients should be given the manufacturer’s patient information leaflet.

Page 12: An introduction to PGDs and Varenicline

Other responsibilities

• Signing up mechanism required.• Named person to be responsible for maintaining

the file.• System for review and updating.• Distribution.• Questions?

Page 13: An introduction to PGDs and Varenicline
Page 14: An introduction to PGDs and Varenicline

Completing the voucher• The Stop Smoking Advisor (Specialist Service or

LES) will complete the first 3 sections of the voucher – client details, advisor details & request titration or maintenance pack

• The dispensing pharmacist must complete the date of supply, inclusion/exclusion criteria, client consent and sign the voucher at the bottom of the form.

Page 15: An introduction to PGDs and Varenicline

Inclusion/exclusion criteria1. Aged 18 or above

2. Tobacco dependant & sufficiently motivated to stop smoking

3. Agreed to behavioural support during course of Varenicline

Is the client currently:

4. Pregnant or breastfeeding?

Does the client have a history of:

5. Renal disease?

6. Epilepsy?

7. Sensitivity to Varenicline or any of its excipients?

8. Psychiatric illness?

All clients must answer YES to Questions 1-3 to be eligible.

If clients answer YES to any of Questions 4 -8, not eligible for Varenicline via the PGD.

Page 16: An introduction to PGDs and Varenicline

Quick Questions??1) According to the PGD what would you supply on

the 1st Supply?2) What would you do if the person arrives for the

second supply 4 weeks after receiving supply 1?3) Can you issue varenicline under a PGD you

haven’t signed? 4) Can you supply to a pregnant woman under this

PGD?5) Can you supply if the person indicates they wont

access behavioral support?

Page 17: An introduction to PGDs and Varenicline

Useful resources

www.medicines.org.uk

www.bnf.org

Page 18: An introduction to PGDs and Varenicline

Varenicline (Champix) ▼

• CHAMPIX is indicated for smoking cessation in adults.

• Black triangle status and MHRA advice.• http://www.mhra.gov.uk/Safetyinformation/DrugS

afetyUpdate/CON087901

Page 19: An introduction to PGDs and Varenicline

Dose• The recommended dose is 1 mg varenicline

twice daily following a 1-week titration as follows:

Days 1 – 3: 0.5 mg once daily

Days 4 – 7: 0.5 mg twice daily

Day 8 – End of treatment 1 mg twice daily

Page 20: An introduction to PGDs and Varenicline

Treatment

• The patient should set a date to stop smoking. CHAMPIX dosing should usually start at 1-2 weeks before this date.

• Patients who cannot tolerate adverse reactions of CHAMPIX may have the dose lowered temporarily or permanently to 0.5 mg twice daily.

• Patients should be treated with CHAMPIX for 12 weeks.

Page 21: An introduction to PGDs and Varenicline

Effect of smoking cessationPhysiological changes resulting from smoking cessation, with or without treatment with CHAMPIX, may alter the pharmacokinetics or pharmacodynamics of some medicinal products, for which dosage adjustment may be necessary (examples include theophylline, warfarin and insulin).

Page 22: An introduction to PGDs and Varenicline

Neuropsychiatric symptoms• Changes in behaviour or thinking, anxiety,

psychosis, mood swings, aggressive behaviour, depression, suicidal ideation and behaviour and suicide attempts have been reported in patients attempting to quit smoking with CHAMPIX.

• Depressed mood, rarely including suicidal ideation and suicide attempt, may be a symptom of nicotine withdrawal.

Page 23: An introduction to PGDs and Varenicline

Cardiovascular events • Certain cardiovascular events were reported

more frequently in patients treated with CHAMPIX.

• Patients taking CHAMPIX should be instructed to notify their doctor of new or worsening cardiovascular symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction or stroke.

Page 24: An introduction to PGDs and Varenicline

Reporting adverse reactions• Compliance and adverse reactions will be monitored at

the bi-weekly follow-up.• Staff will report all adverse reactions in accordance with

the UK Adverse Drug Reaction Reporting Guidelines (Yellow card system available at; http://www.yellowcard.gov.uk/).

• Clients who report agitation/ depression/ suicide ideation /change of mood or new or worsening cardiovascular symptoms must stop treatment immediately and seek prompt medical advice.

Page 25: An introduction to PGDs and Varenicline

Any Questions or Comments?